Hospital Surveillance

A subset of countries and areas monitor severe disease related to influenza virus infection by surveillance of

 

1) hospitalized laboratory-confirmed influenza cases in ICUs or other wards, or

 

2) severe acute respiratory infection (SARI).

 

Laboratory-confirmed hospitalized cases

1.1) Hospitalized laboratory-confirmed influenza cases – ICUs  

 

For week 18/2022, 2 laboratory-confirmed influenza cases were reported from ICU wards (in Czechia and Sweden). The patients were infected with influenza A virus, only 1 of which was ascribed to a subtype and it was A(H3).

 

Since week 40/2021, more influenza type A (n=738, 97.6%) than type B (n=18, 2.4%) viruses were detected (in Czechia, France, Ireland, Sweden and United Kingdom (England)). Of 153 subtyped influenza A viruses, 60% were A(H3) and 40% were A(H1)pdm09. No influenza B viruses were ascribed to a lineage. Of 552 cases with known age, 247 were 15-64 years old, 195 were 65 years and older, 57 were 0-4 years old and 53 were 5-14 years old.

 

1.2) Hospitalized laboratory-confirmed influenza cases – other wards

   

For week 18/2022, 7 laboratory-confirmed influenza cases were reported from other wards (in Czechia and Ireland). Only influenza type A viruses were detected. Only one influenza type A virus was assigned to a subtype, and it was A(H3).

 

Since week 40/2021, 510 influenza type A viruses and 2 influenza type B viruses were detected (in Czechia, Ireland and Ukraine). Of 134 subtyped influenza A viruses, 99% were A(H3) and 1% A(H1)pdm09. The 512 cases with known age fell in 4 age groups: 217 were 65 years and older, 193 were 15-64 years old, 69 were 0-4 years old and 33 were 5-14 years old.

 

Hospital unit